Format

Send to

Choose Destination
Int J Mol Sci. 2016 Aug 30;17(9). pii: E1433. doi: 10.3390/ijms17091433.

Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type.

Author information

1
Institut Jean Godinot, Unicancer, 1 rue du Général Koenig, F-51726 Reims, France. fabrejoseph@yahoo.fr.
2
Université Reims-Champagne-Ardenne, DERM-I-C, EA7319, 51 rue Cognacq-Jay, F-51095 Reims, France. fabrejoseph@yahoo.fr.
3
Centre Hospitalo-Universitaire Henri Mondor, Service de Radiothérapie, 51 Avenue du Maréchal de Lattre de Tassigny, F-94010 Créteil, France. fabrejoseph@yahoo.fr.
4
Institut Jean Godinot, Unicancer, 1 rue du Général Koenig, F-51726 Reims, France. jerome.giustiniani@gmail.com.
5
Université Reims-Champagne-Ardenne, DERM-I-C, EA7319, 51 rue Cognacq-Jay, F-51095 Reims, France. jerome.giustiniani@gmail.com.
6
Institut Jean Godinot, Unicancer, 1 rue du Général Koenig, F-51726 Reims, France. Christian.GARBAR@reims.unicancer.fr.
7
Université Reims-Champagne-Ardenne, DERM-I-C, EA7319, 51 rue Cognacq-Jay, F-51095 Reims, France. Christian.GARBAR@reims.unicancer.fr.
8
Université Reims-Champagne-Ardenne, DERM-I-C, EA7319, 51 rue Cognacq-Jay, F-51095 Reims, France. frank.antonicelli@univ-reims.fr.
9
Institut Jean Godinot, Unicancer, 1 rue du Général Koenig, F-51726 Reims, France. yacine.merrouche@reims.unicancer.fr.
10
Université Reims-Champagne-Ardenne, DERM-I-C, EA7319, 51 rue Cognacq-Jay, F-51095 Reims, France. yacine.merrouche@reims.unicancer.fr.
11
Institut National de la Santé et de la Recherche Médicale (INSERM) U976, Hôpital Saint Louis, F-75010 Paris, France. armand.bensussan@inserm.fr.
12
Université Paris Diderot, Sorbonne Paris Cité, Laboratoire Immunologie Dermatologie & Oncologie, UMR-S 976, F-75475 Paris, France. armand.bensussan@inserm.fr.
13
OREGA Biotech, 69130 Ecully, France. armand.bensussan@inserm.fr.
14
Institut National de la Santé et de la Recherche Médicale (INSERM) U976, Hôpital Saint Louis, F-75010 Paris, France. martine.bagot@aphp.fr.
15
Université Paris Diderot, Sorbonne Paris Cité, Laboratoire Immunologie Dermatologie & Oncologie, UMR-S 976, F-75475 Paris, France. martine.bagot@aphp.fr.
16
Université Paris Diderot, Sorbonne Paris Cité, Laboratoire Immunologie Dermatologie & Oncologie, UMR-S 976, F-75475 Paris, France. reem.al-daccak@inserm.fr.

Abstract

The inflammatory process contributes to immune tolerance as well as to tumor progression and metastasis. By releasing extracellular signals, cancerous cells constantly shape their surrounding microenvironment through their interactions with infiltrating immune cells, stromal cells and components of extracellular matrix. Recently, the pro-inflammatory interleukin 17 (IL-17)-producing T helper lymphocytes, the Th17 cells, and the IL-17/IL-17 receptor (IL-17R) axis gained special attention. The IL-17 family comprises at least six members, IL-17A, IL-17B, IL-17C, IL-17D, IL-17E (also called IL-25), and IL-17F. Secreted as disulfide-linked homo- or heterodimers, the IL-17 bind to the IL-17R, a type I cell surface receptor, of which there are five variants, IL-17RA to IL-17RE. This review focuses on the current advances identifying the promoting role of IL-17 in carcinogenesis, tumor metastasis and resistance to chemotherapy of diverse solid cancers. While underscoring the IL-17/IL-17R axis as promising immunotherapeutic target in the context of cancer managing, this knowledge calls upon further in vitro and in vivo studies that would allow the development and implementation of novel strategies to combat tumors.

KEYWORDS:

cancer; immunotherapy; interleukin 17 (IL-17); tumor microenvironment

PMID:
27589729
PMCID:
PMC5037712
DOI:
10.3390/ijms17091433
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center